CoChat

Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials

Open access

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Diabetes is defined by its association with hyperglycemia-specific microvascular complications; however, it also imparts a two- to fourfold risk of cardiovascular disease (CVD). Although microvascular complications can lead to significant morbidity and premature mortality, by far the greatest cause of death in people with diabetes is CVD. Results from randomized controlled trials have demonstrated conclusively that the risk of microvascular complications can be reduced by intensive glycemic control in patients with type 1 (1,2) and type 2 diabetes (3–5). In the Diabetes Control and Complications Trial (DCCT), there was an ∼60% reduction in development or progression of diabetic retinopathy, nephropathy, and neuropathy between the intensively treated group (goal A1C <6.05%, mean achieved A1C ∼7%) and the standard group (A1C ∼9%) over an average of 6.5 years. The relationship between glucose control (as reflected by the mean on-study A1C value) and risk of complications was log-linear and extended down to the normal A1C range (<6%) with no threshold noted. In the UK Prospective Diabetes Study (UKPDS), participants newly diagnosed with type 2 diabetes were followed for 10 years, and intensive control (median A1C 7.0%) was found to reduce the overall microvascular complication rate by 25% compared with conventional treatment (median A1C 7.9%). Here, too, secondary analyses showed a continuous relationship between the risk of microvascular complications and glycemia extending into the normal range of A1C, with no glycemic threshold. On the basis of these two large controlled trials, along with smaller studies and numerous epidemiologic reports, the consistent findings related to microvascular risk reduction with intensive glycemic control have led the American Diabetes Association (ADA) to recommend an A1C goal of <7% for most adults with diabetes (6), recognizing that more or less stringent goals may be appropriate for certain patients. Whereas many epidemiologic studies and meta-analyses …

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc08-9026

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 1

  1. Duckworth W, Abraira C, Moritz T, Reda D, Emannele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vikek ME, Henderson WG, Huang GD: Intensive glucose control and complications in American veterans with type 2 diabetes. N Engl J Med. In press

Cited by

Metadata

Authors
Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., & Sherwin, R. S.
Affiliations
  • University of Miami (US)
  • Park Nicollet Clinic (US)
  • Northwestern University (US)
  • University of North Carolina at Chapel Hill (US)
  • University of California, San Francisco (US)
  • University of Bristol (GB)
  • American Diabetes Association (US)
  • Saint Luke's Hospital (US)
  • Carl T. Hayden Veterans Affairs Medical Center (US)
  • Yale University (US)
Venue
Diabetes Care
Published
2009-01-01
Volume
32
Issue
1
Pages
187-192
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2181092548
Cited by
881
References
22
Citations by year
2026: 6 · 2025: 12 · 2024: 13 · 2023: 24 · 2022: 23 · 2021: 32 · 2020: 37 · 2019: 40 · 2018: 43 · 2017: 46 · 2016: 53 · 2015: 70 · 2014: 56 · 2013: 68 · 2012: 101
FWCI
62.17
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • Amylin Pharmaceuticals
  • Sanofi
  • Edwards Lifesciences
  • Osiris Therapeutics
  • Insulet Corporation
  • MannKind Corporation
  • Halozyme
  • Dexcom
  • Tandem Diabetes Care
  • Daiichi-Sankyo
  • Novo Nordisk
  • Pfizer Pharmaceuticals
  • Daiichi Sankyo Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
tight glycemic control, cardiovascular events, type 1 diabetes, type 2 diabetes, microvascular complications, HbA1c targets, ACCORD trial, ADVANCE trial, Diabetes Control and Complications Trial, UKPDS, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, cardiovascular risk
MeSH terms
Adult, Aged, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Homeostasis, Humans, Hyperglycemia, Middle Aged, Risk Factors, Sensitivity and Specificity, Randomized Controlled Trials as Topic, Risk Assessment, Diabetes Complications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.